- Home
- WAI vs GLTO Comparison
WAI vs GLTO Comparison
Compare WAI & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAI
- GLTO
- Stock Information
- Founded
- WAI 2018
- GLTO 2011
- Country
- WAI China
- GLTO Denmark
- Employees
- WAI N/A
- GLTO N/A
- Industry
- WAI
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- WAI
- GLTO Health Care
- Exchange
- WAI NYSE
- GLTO Nasdaq
- Market Cap
- WAI 5.5M
- GLTO 4.5M
- IPO Year
- WAI 2023
- GLTO 2020
- Fundamental
- Price
- WAI $0.48
- GLTO $3.75
- Analyst Decision
- WAI
- GLTO Buy
- Analyst Count
- WAI 0
- GLTO 1
- Target Price
- WAI N/A
- GLTO $10.00
- AVG Volume (30 Days)
- WAI 5.9M
- GLTO 26.0K
- Earning Date
- WAI 08-24-2025
- GLTO 08-11-2025
- Dividend Yield
- WAI N/A
- GLTO N/A
- EPS Growth
- WAI N/A
- GLTO N/A
- EPS
- WAI N/A
- GLTO N/A
- Revenue
- WAI $3,750,352.00
- GLTO N/A
- Revenue This Year
- WAI N/A
- GLTO N/A
- Revenue Next Year
- WAI N/A
- GLTO N/A
- P/E Ratio
- WAI N/A
- GLTO N/A
- Revenue Growth
- WAI N/A
- GLTO N/A
- 52 Week Low
- WAI $0.41
- GLTO $2.01
- 52 Week High
- WAI $20.00
- GLTO $15.13
- Technical
- Relative Strength Index (RSI)
- WAI N/A
- GLTO 59.58
- Support Level
- WAI N/A
- GLTO $3.40
- Resistance Level
- WAI N/A
- GLTO $3.90
- Average True Range (ATR)
- WAI 0.00
- GLTO 0.33
- MACD
- WAI 0.00
- GLTO 0.01
- Stochastic Oscillator
- WAI 0.00
- GLTO 58.13
About WAI TOP KINGWIN LTD
Top KingWin Ltd operates as a corporate business training and consulting company, providing personal and management training and financial consulting services. It provides some essential business services in China to young and emerging companies, including corporate business training services, which mainly focus on knowledge and new perspectives on the capital markets; corporate consulting services, which mainly focus on various aspects of fundraising; and advisory and transaction services. Its main clients are entrepreneurs and executives in China's small and medium enterprises (SMEs).
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.